There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.
Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has.
Potential...
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
Interesting Charts From the Day we Discovered it.
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
